Cargando…
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial
AIMS: Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation/atrial flutter (AF/AFL), it is im...
Autores principales: | Vamos, Mate, Oldgren, Jonas, Nam, Gi-Byoung, Lip, Gregory Y H, Calkins, Hugh, Zhu, Jun, Ueng, Kwo-Chang, Ludwigs, Ulf, Wieloch, Mattias, Stewart, John, Hohnloser, Stefan H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175188/ https://www.ncbi.nlm.nih.gov/pubmed/34958366 http://dx.doi.org/10.1093/ehjcvp/pvab090 |
Ejemplares similares
-
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study
por: Vamos, Mate, et al.
Publicado: (2019) -
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial
por: Blomström-Lundqvist, Carina, et al.
Publicado: (2023) -
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020) -
Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter
por: Curtis, Anne B, et al.
Publicado: (2021) -
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)